New 340B report from Minnesota exposes steep hospital markups on medicines, patient benefits remain unclear phrma.org/Blog/New-340B-…

A new report from the Minnesota Department of Health shows the #340B program in Minnesota disproportionately benefits large hospital systems and for-profit middlemen, like contract pharmacies and third-party administrators, raising serious concerns about whether vulnerable

#ICYMI: PhRMA joined Colorado Politics to discuss how the rapidly growing #340B program leaves Colorado patients and underserved communities behind. Watch the full video: coloradopolitics.com/colorado-polit…

Today, at the inaugural PhRMA Forum, we’re bringing together diverse voices to discuss how we can chart the course to a healthier America. At the foundation of this discussion is our new Innovation Report that explores how biopharmaceutical innovation prevents disease,

Kicking off PhRMA Forum with opening remarks from Daniel O’Day, Chairman & CEO Gilead Sciences and PhRMA Board Chair, who shared an inspiring message: With the right policies, we can fuel innovation, expand access, and build a stronger, patient-centered health care system—where

Americans for Tax Reform explains how expanding the #340B drug discount program, without needed reforms, will raise health care costs for North Dakotans. atr.org/north-dakota-l…

Bad actor hospitals are abusing the system with 340B markups --- a hidden tax, increasing costs for employers, straining state and federal budgets phrma.org/blog/340b-mark…

Without #ClinicalTrials, we wouldn’t have groundbreaking, life-saving medicines. Plus, in 2023 alone, biopharmaceutical clinical trials pumped over $30 billion directly into the U.S. economy with even more indirectly contributed. Explore how these trials fuel both innovation and

Clinical trials funded by pharmaceutical companies in Ohio boosted the state economy by $2.4 billion in 2023. How much did your state see? cleveland.com/medical/2025/0…

New research: Industry sponsored clinical trials generate more than $62 billion in American economic activity. phrma.org/blog/new-resea…

x.com/mattjay/status…

Like so many government pricing schemes before it, MFN won’t lower out-of-pocket costs for American patients because it fails to address one of the real reasons patients in the U.S. are paying more. phrma.org/blog/how-the-3…

Patients, taxpayers and employers are footing the bill while some large #340B hospitals in Ohio are profiting from discounted drugs and spending those profits on vanity projects like stadiums instead of care. This isn’t reform. It’s abuse. We need #340BReform.

ICYMI: Ubl - Forget Foreign Price Controls: There’s a better solution to lowering drug prices phrma.org/blog/icymi-for…

Patients and employers are all saddled with a hidden tax. It’s time for Congress to fix 340B. See the latest analysis from Ohio exposing growing abuses of the 340B markup program: phrma.org/blog/latest-an…

Since the 20th century, vaccines have helped drive down disease rates and turn once-deadly illnesses into largely preventable ones. Learn more about vaccine innovation and how vaccines are helping to build a healthier future for Americans. #NIAM

We’re launching “Meet Mark,” a new ad campaign that highlights how the 340B hospital markup program is driving up costs for patients, taxpayers and employers. Meet Mark and learn more about 340B abuses here:

Middlemen and 340B are siphoning dollars from patients and states phrma.org/blog/why-state…

California’s #SB41 is now law. PBMs have gamed the system for far too long—those days are over. Thanks to bipartisan support, California has enacted landmark PBM reform that enhances transparency, accountability & delivers more savings to patients at the pharmacy counter.

Over the weekend, California enacted landmark reform that increases PBM transparency & corrects how they are compensated so they are not incentivized to favor higher-priced medicines. This is a win for patients. I recently shared some thoughts in GOVERNING about how the states